Since the start of 2008, at least 19 companies in
Biogen Idec's main areas of interest - autoimmune, cancer, cardiovascular and
neurology - were acquired for $500 million or more. (A) Status of programs at
the time of the deal. Source: BCIQ: BioCentury Online Intelligence
|
Year
|
Target
|
Acquirer
|
Value
|
Major
assets (A)
|
|
2010
(prop)
|
Abraxis
BioScience Inc. (NASDAQ:ABII)
|
Celgene
Corp. (NASDAQ:CELG)
|
$2.9B
plus $650M milestones
|
Breast
cancer drug Abraxane nab-paclitaxel, with 2009 revenues of $314.5
|
|
2010
(prop)
|
TargeGen
Inc.
|
sanofi-aventis
Group (Euronext:SAN; NYSE:SNY)
|
$75M
plus $485M milestones
|
Small
molecule kinase inhibitors, including lead compound TG 101348, which has
completed a Phase I/II trial to treat myelofibrosis
|
|
2010
|
Corthera Inc.
|
Novartis AG (NYSE:NVS;
SIX:NOVN)
|
$120M plus $500M milestones
|
Relaxin recombinant human relaxin-H2 in Phase III
testing to treat acute decompensated heart failure
|